TY - JOUR
T1 - Peripheral Blood Biomarkers for Rheumatoid Arthritis–Associated Interstitial Lung Disease
T2 - A Systematic Review
AU - Van Kalsbeek, Daniel
AU - Brooks, Rebecca
AU - Shaver, Dawson
AU - Ebel, Ariadne
AU - Hershberger, Daniel
AU - Schmidt, Cynthia
AU - Poole, Jill A.
AU - Ascherman, Dana P.
AU - Thiele, Geoffrey M.
AU - Mikuls, Ted R.
AU - England, Bryant R.
N1 - Funding Information:
There was no funding directly supporting the conduct of this study. The authors disclose the following funding support: Dr. Poole's work was supported by the Department of Defense (PR200793) and the National Institute for Occupational Safety and Health (R01‐OH‐012045 and U54‐OH‐010162). Dr. Mikuls's work was supported by the VA Biomedical Laboratory Research and Development (I01 BX004660), the Department of Defense (PR200793), the Rheumatology Research Foundation, and the National Institute of General Medical Sciences (U54‐GM‐115458). Dr. England's work was supported by the VA Clinical Science Research and Development (IK2 CX002203), the Rheumatology Research Foundation, and the National Institute of General Medical Sciences (U54‐GM‐115458), which funds the Great Plains Institutional Development Award for Clinical and Translational Research Network.
Publisher Copyright:
© 2023 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
PY - 2023/4
Y1 - 2023/4
N2 - Background: Biomarkers have been proposed as tools to aid in the identification and prognostication of interstitial lung disease (ILD) in rheumatoid arthritis (RA). We performed a systematic review of studies evaluating peripheral blood biomarkers and their association with RA-ILD and its prognosis. Methods: Medline, Embase, the Cochrane Library, and Scopus were queried for relevant studies, with the final search update on July 12, 2021. We included studies evaluating peripheral blood biomarkers for the identification and/or prognostication of RA-ILD, extracting the performance of individual biomarkers for identifying RA-ILD, and predicting prognosis. Modified versions of the Quality Assessment of Diagnostic Accuracy Studies 2 and the Quality in Prognosis Studies tools were used for quality assessment. Results: Seventy studies met eligibility criteria. Study and patient characteristics, analytical methods, strength and consistency of associations, and study quality were heterogeneous. A total of 92 biomarkers were positively associated and 12 were negatively associated with RA-ILD among patients with RA in one or more report. Only a small number of biomarkers were evaluated in multiple cohorts using adjusted analyses. Biomarkers most strongly associated with RA-ILD overlapped with those identified for idiopathic pulmonary fibrosis. Few prognostic biomarkers of RA-ILD were identified. Conclusion: Several peripheral blood biomarkers are associated with the presence of RA-ILD, but few have been assessed in multivariable models, have been externally validated, have discriminated RA-ILD from other lung disease, or have prognosticated the disease course. High-quality studies investigating and validating peripheral biomarkers in RA-ILD are needed before they can be employed in clinical care.
AB - Background: Biomarkers have been proposed as tools to aid in the identification and prognostication of interstitial lung disease (ILD) in rheumatoid arthritis (RA). We performed a systematic review of studies evaluating peripheral blood biomarkers and their association with RA-ILD and its prognosis. Methods: Medline, Embase, the Cochrane Library, and Scopus were queried for relevant studies, with the final search update on July 12, 2021. We included studies evaluating peripheral blood biomarkers for the identification and/or prognostication of RA-ILD, extracting the performance of individual biomarkers for identifying RA-ILD, and predicting prognosis. Modified versions of the Quality Assessment of Diagnostic Accuracy Studies 2 and the Quality in Prognosis Studies tools were used for quality assessment. Results: Seventy studies met eligibility criteria. Study and patient characteristics, analytical methods, strength and consistency of associations, and study quality were heterogeneous. A total of 92 biomarkers were positively associated and 12 were negatively associated with RA-ILD among patients with RA in one or more report. Only a small number of biomarkers were evaluated in multiple cohorts using adjusted analyses. Biomarkers most strongly associated with RA-ILD overlapped with those identified for idiopathic pulmonary fibrosis. Few prognostic biomarkers of RA-ILD were identified. Conclusion: Several peripheral blood biomarkers are associated with the presence of RA-ILD, but few have been assessed in multivariable models, have been externally validated, have discriminated RA-ILD from other lung disease, or have prognosticated the disease course. High-quality studies investigating and validating peripheral biomarkers in RA-ILD are needed before they can be employed in clinical care.
UR - http://www.scopus.com/inward/record.url?scp=85149331828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149331828&partnerID=8YFLogxK
U2 - 10.1002/acr2.11535
DO - 10.1002/acr2.11535
M3 - Article
C2 - 36852564
AN - SCOPUS:85149331828
SN - 2578-5745
VL - 5
SP - 201
EP - 226
JO - ACR Open Rheumatology
JF - ACR Open Rheumatology
IS - 4
ER -